BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery

BU-CMD 化学图书馆联盟：促进化学家和生物学家之间的合作以促进转化发现

• 批准号: 10078285
• 负责人: JOHN A PORCO
• 金额: $ 67.49万
• 依托单位: BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10078285
• 关键词: Animal Model; Architecture; Area; Arts; Automation; Biological; Biological Assay; Biology; Boston; CLC Gene; California; Charge; Chemicals; Chemistry; Chicago; Clinical and Translational Science Awards; Collaborations; Collection; Complement; Complex; Disease; Fostering; Foundations; Gap Junctions; Goals; Grant; Hand; Health; Human; Industrialization; Infrastructure; Institution; Intake; Laboratories; Lead; Los Angeles; Massachusetts; Methods; Miniaturization; Modeling; Molecular; Neurodegenerative Disorders; New York; North Carolina; Oncology; Organic Synthesis; Pharmaceutical Chemistry; Rare Diseases; Research; Research Personnel; Research Project Grants; Resources; Scientist; Screening Result; Seeds; Site; Structure; Technology; Testing; Therapeutic; Therapeutic Agents; Translating; Translations; United States National Institutes of Health; Universities; Vendor; analog; base; biological systems; chemical bond; cohort; design; drug development; drug discovery; experience; follow-up; human disease; improved; innovation; interest; medical schools; pre-clinical; programs; scaffold; screening; skills; small molecule; small molecule libraries; therapeutically effective; tool; translational scientist

PROJECT SUMMARY AND ABSTRACT BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery Small molecules are powerful tools for understanding biological systems, and form the foundation for most therapies of human disease. The successful translation of a bioactive small molecule into a safe, effective therapeutic requires the collective involvement of both chemists and biologists. The Boston University Center for Molecular Discovery (BU-CMD) is a laboratory that connects chemists who make molecules with biologists who wish to test them in various diseases. The BU-CMD serves as a collaborative nexus that bridges these connections, seeding new discoveries and providing the critical chemistry support required to further develop existing leads. The objective of this program is to leverage existing BU-CMD resources across multiple CTSA hubs, establishing an expandable molecule distribution infrastructure for seeding and fostering collaborative research projects between chemists and translational scientists. The overarching goal of the project is to advance curative research for challenging biological disease areas. The BU-CMD has longstanding experience in curating and openly distributing a small molecule screening collection of diverse, structurally complex chemotypes, through a unique, homegrown consortium of biological screeners called the Chemical Library Consortium ("CLC"). The CLC has been unique in its ability to enable new discoveries and foster meaningful collaborative follow-up on these discoveries toward translational drug discovery. This proposal describes the formal connection of the CLC with the CTSA through the establishment of an open access, CTSA-based compound sharing network centered at Boston University. The proposed U01 program will curate molecules from synthetic organic chemists at six CTSA hubs (Boston University, New York University, University of North Carolina, Chapel Hill, University of California Los Angeles, The University of Chicago, and University of Notre Dame) and will distribute them within the CLC network. The CLC network will be expanded as part of this grant to include new translational scientists at the Vanderbilt University and University of Massachusetts Medical School hubs. Lastly, a formal connection will be forged between the BU-CMD and NCATS in order to connect translational scientists to resources and technologies developed herein. This consortium aims to connect scientific resources across CTSA hubs, and seed new collaborations between translational scientists at these hubs, and improve upon existing infrastructure for the discovery and progression of small molecule therapies for diseases.

项目摘要和摘要 BU-CMD化学图书馆财团： 促进化学家与生物学家之间的合作进行转化发现 小分子是理解生物系统的强大工具，并为大多数 人类疾病的疗法。成功地将生物活性小分子转换为安全，有效的 治疗需要化学家和生物学家的集体参与。波士顿大学中心 分子发现（BU-CMD）是一个将分子与生物学家制造的化学家联系起来的实验室 希望在各种疾病中测试它们。 BU-CMD充当桥接这些的协作联系 连接，播种新发现并提供进一步发展所需的关键化学支持 现有潜在客户。该计划的目的是利用多个CTSA的现有BU-CMD资源 集线器，建立可扩展的分子分布基础架构，用于播种和促进协作 化学家与转化科学家之间的研究项目。该项目的总体目标是 提前针对挑战生物学疾病领域的治疗研究。 BU-CMD有长期的经验 在策划和公开分布一个小分子筛选的不同，结构复杂的集合 化学型通过一个独特的本土生物学筛查器联盟，称为化学库 财团（“ CLC”）。 CLC在实现新发现并促进有意义的能力方面是独一无二的 这些发现转化药物发现的协作随访。该提议描述了 通过建立开放访问，基于CTSA的正式连接与CTSA 复合共享网络以波士顿大学为中心。提出的U01程序将策划分子 来自六个CTSA枢纽的合成有机化学家（波士顿大学，纽约大学，北大学 卡罗来纳州，教堂山，加利福尼亚大学洛杉矶分校，芝加哥大学和巴黎大学 dame），并将它们在CLC网络中分配。 CLC网络将作为这笔赠款的一部分扩展 包括范德比尔特大学和马萨诸塞大学医学的新翻译科学家 学校枢纽。最后，将在BU-CMD和NCAT之间建立正式的连接，以连接 转化科学家到这里开发的资源和技术。该财团旨在连接 跨CTSA枢纽的科学资源，以及在这些转化科学家之间进行新的合作 集线器，并改善现有的基础设施，以发现和进展小分子疗法 疾病。